Mind Medicine price target lowered to $14 from $16 at Canaccord

Canaccord lowered the firm’s price target on Mind Medicine to $14 from $16 and keeps a Buy rating on the shares. The firm views the stock as signifcantly undervalued following its Q2 results and recent capital raise while noting catalysts are some time away.